News
Eli Lilly said it believes the new data bolsters the case for Mounjaro to be prescribers’ first choice for patients with Type 2 diabetes.
The Covid-19 pandemic turned Moderna and BioNTech into household names almost overnight. Now the two companies find ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback